Enhanced Anti‐tumor Effect of Trastuzumab in Combination with Cisplatin

The oncogenenic transmembrane tyrosine kinase receptor HER–2/neu is a promising target for treatment of HER–2–overexpressing cancers. The humanized anti‐HER–2/neu antibody Trastuzumab is under clinical evaluation in combination with chemotherapy against breast cancer. The combination of Trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Naruse, Ichiro, Fukumoto, Hisao, Saijo, Nagahiro, Nishio, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2002
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927030/
https://www.ncbi.nlm.nih.gov/pubmed/12036454
http://dx.doi.org/10.1111/j.1349-7006.2002.tb01293.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927030/
https://www.ncbi.nlm.nih.gov/pubmed/12036454
http://dx.doi.org/10.1111/j.1349-7006.2002.tb01293.x

Ejemplares similares